SCHEMBL17176552

SCHEMBL17176552

CCC1(C)CCN(Cc2cccs2)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.57
DRD4 P21917 10/20 0.51
DRD3 P35462 7/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HSD17B10 Q99714 2/20 0.51
SIGMAR1 Q99720 1/20 0.50
DRD2 P14416 5/20 0.48
DRD5 P21918 4/20 0.48
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 2/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
DRD1 P21728 1/20 0.45
TSHR P16473 2/20 0.43
ALOX15 P16050 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18202990 0.85 HTT (0.62) HTTDRD4DRD3SMN1; SMN2HSD17B10
SCHEMBL18199701 0.80 HTT (0.55) HTTDRD4DRD3SMN1; SMN2HSD17B10
SCHEMBL19323807 0.80 HTT (0.55) HTTDRD4DRD3SMN1; SMN2HSD17B10
SCHEMBL31653519 0.79 HTT (0.62) HTTDRD4DRD3SMN1; SMN2HSD17B10
SCHEMBL7654044 0.76 HTT (0.68) HTTDRD4DRD3SMN1; SMN2HSD17B10
SCHEMBL7050984 0.76 HTT (0.72) HTTDRD4DRD3SMN1; SMN2HSD17B10
SCHEMBL21581203 0.75 DRD4 (0.59) HTTDRD4DRD3SMN1; SMN2HSD17B10
SCHEMBL8168957 0.74 HTT (0.70) HTTDRD4DRD3SMN1; SMN2HSD17B10
SCHEMBL2975841 0.74 HTT (0.70) HTTDRD4DRD3SMN1; SMN2HSD17B10
SCHEMBL12424273 0.74 JAK2 (0.36) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170066732-A1 ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE Jiangsu Kanion pharmaceutical CO. LTD (CN) 2017-03-09 US disclosed
WO-2016124129-A1 DIAZA-BENZOFLUORANTHRENE COMPOUNDS 南京明德新药研发股份有限公司 2016-08-11 WO disclosed
WO-2016008381-A1 PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF 辰欣药业股份有限公司 2016-01-21 WO disclosed
WO-2015192760-A1 PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS PI3K INHIBITOR 南京明德新药研发股份有限公司 2015-12-23 WO disclosed
WO-2015165340-A1 ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE 南京明德新药研发股份有限公司 2015-11-05 WO disclosed
WO-2015154630-A1 ANALOGUES OF 4H-PYRAZOLO[1,5-Α]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS 南京明德新药研发股份有限公司 2015-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066732-A1 ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE EIF2AK2, GTF3C5, GTF3C1 HTT 4098/4885DRD4 1552/4885DRD3 2099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.